No connection

Search Results

Corporate Score 30 Neutral

Immunic Names Michael Panzara as Chief Medical Officer

Apr 28, 2026 10:50 UTC
IMUX
Medium term

Immunic, Inc. has appointed Michael Panzara to lead its clinical and regulatory development strategies. Panzara succeeds Andreas Muehler in the role, effective April 24, 2026.

  • Michael Panzara appointed as CMO
  • Oversees clinical, medical, and regulatory affairs
  • Previous experience as CMO of Neurvati Neurosciences
  • Equity grant of 300,000 common stock shares
  • Shares traded at $9.70 (-2.81%) in pre-market

Immunic, Inc. (IMUX) announced on Tuesday the appointment of Michael Panzara as its new Chief Medical Officer. Panzara, who officially assumed the role on April 24, 2026, succeeds Andreas Muehler. In this executive capacity, Panzara will be responsible for leading the company's entire development organization. His remit includes the management of clinical development, medical affairs, and regulatory affairs. Beyond operational oversight, Panzara will act as a key strategic partner to the company's CEO and Board of Directors to help define and execute the firm's long-term goals. Panzara joins Immunic following a tenure as Chief Medical Officer at Neurvati Neurosciences, Inc. To align his interests with shareholders, the Compensation Committee of the Board of Directors has granted him an initial equity option to purchase 300,000 shares of common stock under the Immunic, Inc. 2026 Inducement Equity Compensation Plan. In pre-market trading following the announcement, shares of IMUX were priced at $9.70, reflecting a decrease of 2.81% on the Nasdaq.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile